GuidelineEuropean journal of nuclear medicine and molecular imaging2023
Joint EANM/SNMMI procedure guideline for the use of
Open access · hybridAbstract readPractice Guideline
In one paragraph
Guideline in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 147 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
147citing papers in PubMed, 5 pooled it
59.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
147 citing papers in PubMed, 5 syntheses or guidelines pooled it, 231 citations in OpenAlex.
- Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer.BJU international · 2026Guideline
- Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2026Pooled it
- Beyond [BMC cancer · 2026Pooled it
- Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use ofClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Guideline
- Assessment of the therapeutic efficacy of [European journal of nuclear medicine and molecular imaging · 2025Pooled it
- Phase 2 Prospective Trial of Retreatment with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Trial
- [European journal of nuclear medicine and molecular imaging · 2025Trial
- Dosimetry and pharmacokinetics of [European journal of nuclear medicine and molecular imaging · 2024Trial
- Adipose triglyceride lipase driven lipolysis as a targetable metabolic vulnerability in prostate cancer with intrinsic metabolic inflexibility.British journal of cancer · 2026Article
- Metformin and renal dosimetry in patients undergoing [European journal of nuclear medicine and molecular imaging · 2026Article
- Real-world evaluation of [European journal of nuclear medicine and molecular imaging · 2026Article
- Real-World Outcomes of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Bridging the PSMA PET/CT access gap in prostate cancer: evidence, barriers, and priorities for implementation.World journal of urology · 2026Review
- Ferroptosis at the Metabolic-Immune Interface in Metastatic Castration-Resistant Prostate Cancer: Mechanistic Evidence, Translational Gaps, and Combination Strategies.Annals of surgical oncology · 2026Review
- Influence of increased injected activities up 9.0 GBq [EJNMMI physics · 2026Article
- Energy-specific attenuation and half-value layers of BaSOAnnals of nuclear medicine · 2026Article
- 177 Lu-PSMA for prostate cancer: progress, challenges and future perspectives.Asian journal of andrology · 2026Review
- Beyond the Fixed Dose in Theranostics: Pragmatic Dosimetry as the Missing Link in Optimizing Precision Nuclear Oncology.World journal of nuclear medicine · 2026Article
- Virtual-patient nonlinear mixed-effects modelling for data-driven optimisation of single-time-point dosimetry: a proof-of-concept study in [EJNMMI physics · 2026Article
- Outcomes of [European journal of nuclear medicine and molecular imaging · 2026Article
87 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 20 institutions in 9 countries.
Clemens KratochwilDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany. clemens.kratochwil@med.uni-heidelberg.de.ORCID http://orcid.org/0000-0003-1334-8260
Wolfgang P FendlerDepartment of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, 45147, Essen, Germany.
Matthias EiberDepartment of Nuclear Medicine, Klinikum Rechts Der Isar, Technical University Munich (TUM), 81675, Munich, Germany.
Michael S HofmanProstate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0001-8622-159X
Louise EmmettDepartment of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney, Darlinghurst, Australia.
Jeremie CalaisAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, CA, USA.
Joseph R OsborneDepartment of Radiology, Weill Cornell Medicine, New York, NY, 10021, USA.
Amir IravaniDepartment of Radiology, University of Washington School of Medicine, Seattle, WA, USA.
Phillip KooDivision of Diagnostic Imaging, Banner MD Anderson Cancer Center, Gilbert, AZ, USA.
Liza LindenbergMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Richard P BaumCuranosticum Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany.
Murat Fani BozkurtHacettepe University Faculty of Medicine, Department of Nuclear Medicine, Ankara, Turkey.ORCID http://orcid.org/0000-0003-2016-2624
Roberto C Delgado BoltonDepartment of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), Logroño (La Rioja), Spain.ORCID http://orcid.org/0000-0002-8071-6513
Samer EzziddinDepartment of Nuclear Medicine, Saarland University Medical Center, Homburg, Germany.
Flavio ForrerDepartment of Radiology and Nuclear Medicine, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Rodney J HicksThe University of Melbourne Department of Medicine, St Vincent's Hospital, Melbourne, Australia.ORCID http://orcid.org/0000-0002-0758-0824
Thomas A HopeDepartment of Radiology and Biomedical Imaging / Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Levent KabasakalDepartment of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University- Cerrahpasa, Istanbul, Turkey.
Mark KonijnenbergRadiology & Nuclear Medicine Department, Erasmus MC, Rotterdam, The Netherlands.
Klaus KopkaHelmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
Michael LassmannDepartment of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Felix M MottaghyDepartment of Nuclear Medicine, RWTH Aachen University Medical Faculty, Aachen, Germany.
Wim J G OyenDepartment of Biomedical Sciences, Humanitas University, and Humanitas Clinical and Research Centre, Department of Nuclear Medicine, Milan, Italy.
Kambiz RahbarDepartment of Nuclear Medicine, University Hospital Muenster, Muenster, Germany.
Heiko SchoderDepartment of Radiology, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Irene VirgoliniDepartment of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria.
Lisa BodeiDepartment of Radiology, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Stefano FantiDivision of Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
Uwe HaberkornDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Ken HermannDepartment of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, 45147, Essen, Germany.
Deutschen Konsortium für Translationale Krebsforschung · DEHeidelberg University · DEMemorial Sloan Kettering Cancer Center · USThe University of Melbourne · AUAzienda USL di Bologna · ITBanner MD Anderson Cancer CenterCornell University · USErasmus MC · NLHacettepe University · TRHelmholtz-Zentrum Dresden-Rossendorf · DEHospital San Pedro · ESHumanitas University · ITInnsbruck Medical University · ATIstanbul University-Cerrahpaşa · TRKantonsspital St. Gallen · CHMaastricht University · NLNational Institutes of Health · USSaarland University · DESt Vincent's Hospital Sydney · AUTUM Klinikum · DE
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified by PSMA PET imaging. Promising results with PSMA-targeted radiopharmaceutical therapy have already been obtained in early-phase studies using various combinations of targeting molecules and radiolabels. Definitive evidence of the safety and efficacy of [
Indexed as
Nuclear MedicineProstatic Neoplasms, Castration-ResistantDipeptidesHeterocyclic Compounds, 1-RingHumansLutetiumMaleProstate-Specific AntigenRadiopharmaceuticalsTreatment OutcomeDipeptidesHeterocyclic Compounds, 1-RingLutetiumProstate-Specific AntigenRadiopharmaceuticals[177Lu]Lu-PSMA-617EANM/SNMMIPSMA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.